Injectable Steroids

Mastabol 100 mg British Dragon Pharmaceuticals

British Dragon Pharmaceuticals

60,00

In Stock (100 available)

Mastabol 100 mg British Dragon Pharmaceuticals (100 mg) — Drostanolone occupies a unique position among injectable steroids: it functions simultaneously as a potent hardening agent and a m…

100 in stock

This product is for laboratory research use only. Not for human consumption.

5+ −10%
10+ −15% Best price
Third-Party Lab Report HPLC verified
CoA available on request — email support@vitalquests.org with the batch code from your vial.
HPLC TestedBatch report available
No Labels on BoxPlain brown parcel
Pay the CourierCash on delivery only
Ships TodayOrder before 14:00
€85+ = free shipping
EU warehouse — no customs, no delays
Tracked via DHL / DPD / InPost

Description

Mastabol 100 mg British Dragon Pharmaceuticals — Drostanolone occupies a unique position among injectable steroids: it functions simultaneously as a potent hardening agent and a mild aromatase inhibitor. This dual action produces a dry, chiseled appearance while actively reducing estrogen-mediated water retention and fat storage. This formulation is dosed at 100 mg per unit.

Key Benefits

  • DHT-derivative — dry, hard, vascular look with no water retention
  • Anti-estrogenic side-activity — mild AI effect
  • Cutting and pre-contest staple, especially at low body-fat
  • Minimal sides at performance doses — clean compound
  • Stacks well with tren, test, and orals for cutting recomp
  • Each unit dosed at 100 mg — see Recommended Dosage below for protocol-specific intake

Recommended Dosage

Research dosing: propionate 300–500 mg/week split EOD or 3×/week; enanthate 400–600 mg/week split twice weekly. Cycles 8–10 weeks (prop) or 10–14 weeks (eno). Pre-contest protocols stretch to final 6 weeks before show.

How It Works

5α-reduced testosterone with a 2α-methyl group. DHT-derivative — does not aromatise. Mild anti-estrogenic activity via aromatase enzyme competition. High AR affinity. Androgenic but not aggressively so at typical doses.

Pharmacokinetics

Propionate ester: plasma half-life ~2 days. Enanthate: ~7 days. Prop needs EOD or M/W/F pinning; eno twice-weekly fine. Steady-state in 2 weeks (prop) or 4 weeks (eno).

Potential Side Effects

Hair-thinning risk for genetically predisposed users — the DHT-derived nature makes it unfriendly to MPB. Oestrogenic sides absent. HDL drops moderately. Mild HPTA suppression recoverable with standard PCT.

Cycle & Stacking Guide

Cutting stack component, 8–14 weeks by ester. Classic pairing: test E 250 mg/week + masteron E 400 mg/week + (optional) tren or winstrol for final weeks. Works best at <15% body fat where the "dry" look actually shows.

Manufacturer Notes

British Dragon Pharmaceuticals is an independent producer in the research-compound market. Before first use, request the batch-specific Certificate of Analysis and confirm the vial’s tamper-evident seal is intact.

Storage & Handling

Store at recommended temperature (15–25°C; peptides and HGH at 2–8°C after reconstitution). Protect from light and moisture. Keep out of reach of children. For research and educational purposes only.

Reviews

There are no reviews yet.

Be the first to review “Mastabol 100 mg British Dragon Pharmaceuticals”

Your email address will not be published. Required fields are marked *

Drostanolone Propionate

Physical & Chemical Properties for Research Purposes
Chemical structure of Drostanolone Propionate (C23H36O3) for laboratory analysis
2D structural representation · PubChem CID 224004 ↗
Chemical Identity
# CAS Registry Number 521-12-0
Σ IUPAC Name [(2R,5S,8R,9S,10S,13S,14S,17S)-2,10,13-trimethyl-3-oxo-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl] propanoate
F Molecular Formula C23H36O3
M Molecular Weight 360.53 g/mol
SMILES CCC(=O)O[C@@H]1CC[C@@H]2[C@H]3CC[C@@H]4CC(=O)[C@@H](C)C[C@]4(C)[C@@H]3CC[C@]12C
InChIKey VDIINQKPRNWKEH-GOGNSEEVSA-N
Melting Point 124-126 °C
Solubility Insoluble in water; soluble in oils
Biological Half-life 2.5 days (IM)
PubChem CID 224004 ↗
Pharmacological Profile
Anabolic Rating 62
Androgenic Rating 25
Aromatization None
Hepatotoxicity None
Detection Time 3 weeks

Clinical Notes

DHT-derived injectable — 2alpha-methyl modification at the A-ring confers resistance to 3alpha-HSD, allowing intact muscle-cell activity. Cannot aromatise. Weak AR binding in skeletal tissue but displaces estradiol from SHBG, increasing free-testosterone fraction of any concurrent testosterone — this is the mechanism behind the hardening clinical picture at low body-fat percentages. Effect is visibly null above 15% body fat; below 12%, the lean-tissue definition response becomes dose-responsive. Propionate ester mandates EOD injection schedule; PIP is common and dose-dependent — low-viscosity MCT or GSO carrier oil reduces it materially. Androgenic effects (scalp, prostate) occur but are limited to DHT-sensitive populations.

Known trade names: Masteron, Drostopro, Mastabol

Data sourced from published pharmacological literature and authoritative chemical databases (PubChem, DrugBank, ChEBI). Provided for identification and research reference only.